Septerna Announces Novel GPCR-targeted Program Acquired by Vertex

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Septerna, a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that it has signed a definitive asset purchase agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired an undisclosed discovery-stage GPCR program. Under the…
Click here to view original post